Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal Cancer

ABSTRACT: This study is a single center, investigator initiated phase II clinical study to evaluate the efficacy and safety of fruquintinib plus Sintilimab as third-line therapy for colorectal cancer

DISEASE(S): Metastasis Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2323156 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR